Kamel H K, Perry H M, Morley J E
Division of Geriatric Medicine, Saint Louis University School of Medicine, St Louis, Missouri, USA.
J Am Geriatr Soc. 2001 Feb;49(2):179-87. doi: 10.1046/j.1532-5415.2001.49040.x.
Estrogen deficiency in women is associated with accelerated bone loss, and estrogen replacement therapy has been proven to be effective in preventing osteoporosis and fractures in postmenopausal women. The introduction of selective estrogen receptor modulators that have an estrogen-like effect on the skeleton but have a different pattern of effects on other tissues may have an important role in the management of osteoporosis in women in the near future. In men, androgen deficiency has been shown to be associated with osteoporosis. Although androgen replacement in hypogonadal men may decrease bone resorption and increase bone mass, long-term placebo-controlled trials are needed to better define the benefits and risks of such therapy before it can be recommended. Sex hormone deficiency is linked to the development of osteoporosis in both women and men. In women, hormonal replacement by estrogen or the newly developed selective estrogen receptor modulators may prevent the development of osteoporosis and its related fractures. In men, there is early evidence that testosterone replacement therapy may enhance bone mass in hypogonadal men.
女性雌激素缺乏与骨质流失加速有关，雌激素替代疗法已被证明对预防绝经后女性的骨质疏松症和骨折有效。引入对骨骼具有雌激素样作用但对其他组织具有不同作用模式的选择性雌激素受体调节剂，可能在不久的将来对女性骨质疏松症的管理中发挥重要作用。在男性中，雄激素缺乏已被证明与骨质疏松症有关。虽然性腺功能减退男性的雄激素替代可能会减少骨吸收并增加骨量，但在推荐这种疗法之前，需要长期的安慰剂对照试验来更好地确定其益处和风险。性激素缺乏与女性和男性骨质疏松症的发生有关。在女性中，通过雌激素或新开发的选择性雌激素受体调节剂进行激素替代可能会预防骨质疏松症及其相关骨折的发生。在男性中，有早期证据表明睾酮替代疗法可能会增加性腺功能减退男性的骨量。
